We confirmed higher response rates in patients with highly proliferative (Ki-67 > 55%) GEP-NEN G3, as described previously by the NORDIC NEC study and the data from Jann et al. (Sorbye et al. 2013; Jann et al. 2020). The gene discussed is MKI67; the disease is neuroendocrine carcinoma.